InspireMD, Inc.

Equities

NSPR

US45779A8466

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-16 EDT			5-day change	1st Jan Change
2.44 ^USD	-0.11%		+1.42%	-13.17%

05-14	Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024
05-14	Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	MT

Inspiremd, Inc. Announces Preliminary Unaudited Sales Results for the Fourth Quarter of 2017

January 10, 2018 at 07:30 am

InspireMD, Inc. announced preliminary unaudited sales results for the fourth quarter of 2017. For the fourth quarter of 2017, the company anticipates sales of approximately $833,000 compared to $322,000 for the same period last year.

Latest news about InspireMD, Inc.

Transcript : InspireMD, Inc., Q1 2024 Earnings Call, May 14, 2024	05-14
Earnings Flash (NSPR) INSPIREMD Posts Q1 Revenue $1.5M, vs. Street Est of $1.9M	05-14	MT
InspireMD, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Transcript : InspireMD, Inc., Q4 2023 Earnings Call, Mar 06, 2024	03-06
Earnings Flash (NSPR) INSPIREMD Posts Q4 Revenue $1.8M	03-06	MT
InspireMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
InspireMD Gets CE Mark Recertification From the European Union	01-31	MT
InspireMD, Inc. Announces Appointment of Pete Ligotti as Executive Vice President and General Manager of North America	01-03	CI
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions	11-27	CI
Transcript : InspireMD, Inc., Q3 2023 Earnings Call, Nov 06, 2023	11-06
Earnings Flash (NSPR) INSPIREMD Reports Q3 Revenue $1.6M	11-06	MT
InspireMD, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Inspiremd, Inc. Presents Positive 30-Day Follow-Up Results from the C-Guard®? U.S. Investigational Device Exemption Clinical Trial	11-01	CI
InspireMD, Inc. Supports CMS? Final National Coverage Determination Expanding Coverage of Carotid Stenting to Include Both Asymptomatic and Standard Risk Patients	23-10-12	CI
InspireMD, Inc. Announces Management Changes	23-10-06	CI
InspireMD Promotes Shane Gleason to Chief Commercial Officer	23-10-03	MT
InspireMD, Inc. Announces Management Appointments	23-10-03	CI
Transcript : InspireMD, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Earnings Flash (NSPR) INSPIREMD Reports Q2 Revenue $1.6M	23-08-08	MT
InspireMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
InspireMD, Inc. Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption Clinical Trial	23-06-26	CI
Piper Sandler Initiates InspireMD at Overweight With $3 Price Target	23-06-12	MT
Alliance Global Adjusts Price Target on InspireMD to $4.75 From $5.15, Maintains Buy Rating	23-05-17	MT
Insider Buy: Inspiremd	23-05-16	MT
Insider Buy: Inspiremd	23-05-16	MT

Chart InspireMD, Inc.

Duration

Period

More charts

Company Profile

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.44 USD

Average target price

4.5 USD

Spread / Average Target

+84.43%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Devices & Implants

	1st Jan change	Capi.
INSPIREMD, INC.	-13.17%	60.97M
SMITH & NEPHEW PLC	-1.48%	12.12B
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD.	-20.95%	6.91B
GLAUKOS CORPORATION	+58.12%	6.72B
INSPIRE MEDICAL SYSTEMS, INC.	-28.32%	4.12B
AXONICS, INC.	+9.22%	3.46B
ENOVIS CORPORATION	-17.21%	2.45B
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD.	-18.86%	1.88B
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD.	-28.80%	1.57B
DOUBLE MEDICAL TECHNOLOGY INC.	-38.19%	1.45B

Medical Devices & Implants